These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 11576376

  • 1. Differential effects of growth hormone therapy in malnourished hemodialysis patients.
    Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G, Frisch H, Hörl WH, Mayer G, Luger A.
    Kidney Int; 2001 Oct; 60(4):1578-85. PubMed ID: 11576376
    [Abstract] [Full Text] [Related]

  • 2. One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients.
    Kotzmann H, Schmidt A, Lercher P, Schuster E, Geyer G, Frisch H, Hörl WH, Mayer G, Luger A.
    Nephron Clin Pract; 2003 Oct; 93(2):C75-82. PubMed ID: 12616034
    [Abstract] [Full Text] [Related]

  • 3. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A.
    J Nephrol; 2004 Oct; 17(1):87-94. PubMed ID: 15151263
    [Abstract] [Full Text] [Related]

  • 4. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 5. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 6. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [Abstract] [Full Text] [Related]

  • 7. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
    Finkenstedt G, Gasser RW, Höfle G, Watfah C, Fridrich L.
    Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
    [Abstract] [Full Text] [Related]

  • 8. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients.
    Chu LW, Lam KS, Tam SC, Hu WJ, Hui SL, Chiu A, Chiu KC, Ng P.
    J Clin Endocrinol Metab; 2001 May; 86(5):1913-20. PubMed ID: 11344184
    [Abstract] [Full Text] [Related]

  • 10. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 11. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB.
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [Abstract] [Full Text] [Related]

  • 12. The effect of recombinant human growth hormone treatment on bone and mineral metabolism in haemodialysis patients.
    Gram J, Hansen TB, Jensen PB, Christensen JH, Ladefoged S, Pedersen FB.
    Nephrol Dial Transplant; 1998 Jun; 13(6):1529-34. PubMed ID: 9641187
    [Abstract] [Full Text] [Related]

  • 13. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [Abstract] [Full Text] [Related]

  • 14. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study.
    Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR.
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):727-35. PubMed ID: 24816144
    [Abstract] [Full Text] [Related]

  • 15. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [Abstract] [Full Text] [Related]

  • 16. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B, Kann PH.
    Med Klin (Munich); 2004 Oct 15; 99(10):569-77. PubMed ID: 15490072
    [Abstract] [Full Text] [Related]

  • 17. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 15; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 18. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.
    Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R.
    J Clin Endocrinol Metab; 1994 Aug 15; 79(2):470-9. PubMed ID: 7519191
    [Abstract] [Full Text] [Related]

  • 19. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.
    Sartorio A, Ortolani S, Galbiati E, Conte G, Vangeli V, Arosio M, Porretti S, Faglia G.
    J Endocrinol Invest; 2001 Apr 15; 24(4):224-30. PubMed ID: 11383908
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May 15; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.